Schwann Cells in Peripheral Neuropathy
Overview
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">Schwann Cells in Peripheral Neuropathy</th>
</tr>
<tr>
<td class="label">Gene</td>
<td>Protein</td>
</tr>
<tr>
<td class="label">[PMP22](/genes/pmp22)</td>
<td>Peripheral Myelin Protein 22</td>
</tr>
<tr>
<td class="label">[MPZ](/genes/mpz)</td>
<td>P0 Protein</td>
</tr>
<tr>
<td class="label">[GJB1](/genes/gjb1)</td>
<td>Connexin-32</td>
</tr>
<tr>
<td class="label">[MFN2](/genes/mfn2)</td>
<td>Mitofusin-2</td>
</tr>
<tr>
<td class="label">[GDAP1](/genes/gdap1)</td>
<td>GDAP1</td>
</tr>
<tr>
<td class="label">Species</td>
<td>Advantage</td>
</tr>
<tr>
<td class="label">Mouse</td>
<td>Genetic tractability, short lifespan</td>
</tr>
<tr>
<td class="label">Zebrafish</td>
<td>Transparent embryos, rapid development</td>
</tr>
<tr>
<td class="label">Rat</td>
<td>Larger nerve size, more tissue</td>
</tr>
<tr>
<td class="label">Pig</td>
<td>Similar nerve architecture to humans</td>
</tr>
<tr>
<td class="label">Drug class</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Gene silencing</td>
<td>PMP22</td>
</tr>
<tr>
<td class="label">cAMP agonists</td>
<td>cAMP signaling</td>
</tr>
<tr>
<td class="label">Neurotrophin mimetics</td>
<td>Trk receptors</td>
</tr>
<tr>
<td class="label">Myelin stabilizers</td>
<td>Myelin proteins</td>
</tr>
<tr>
<td class="label">Antioxidants</td>
<td>ROS pathways</td>
</tr>
<tr>
<td class="label">Year</td>
<td>Discovery</td>
</tr>
<tr>
<td class="label">1886</td>
<td>Charcot-Marie-Tooth disease described</td>
</tr>
<tr>
<td class="label">1970s</td>
<td>PMP22 gene identified</td>
</tr>
<tr>
<td class="label">1991</td>
<td>PMP22 duplication in CMT1A</td>
</tr>
<tr>
<td class="label">2000s</td>
<td>iPSC technology developed</td>
</tr>
<tr>
<td class="label">2010s</td>
<td>CRISPR gene editing</td>
</tr>
<tr>
<td class="label">2020s</td>
<td>Gene silencing therapies in trials</td>
</tr>
</table>
Schwann cells are the primary glial cells of the peripheral nervous system (PNS), providing myelination, metabolic support, and regeneration capacity for axons. These cells play critical roles in maintaining peripheral nerve health and function, and their dysfunction is central to various forms of peripheral neuropathy including [Charcot-Marie-Tooth disease](/diseases/charcot-marie-tooth-disease), [diabetic peripheral neuropathy](/diseases/diabetic-neuropathy), and [Guillain-Barré syndrome](/diseases/guillain-barre-syndrome). [@scherer2008]
This page provides a comprehensive overview of Schwann cell biology, their role in peripheral neuropathies, and emerging therapeutic strategies targeting these cells.
Normal Schwann Cell Biology
Myelinating Schwann Cells
Myelinating Schwann cells wrap large-diameter axons (greater than 1 μm diameter) with a multilamellar myelin sheath, providing saltatory conduction of action potentials that dramatically increases nerve conduction velocity. This myelination process involves the coordinated expression of specific myelin proteins including [P0 (MPZ gene)mpz), [Peripheral Myelin Protein 22 (PMP22 gene)pmp22), and [Myelin Basic Protein (MBP gene)mbp). [@nave2010]
The formation and maintenance of the myelin sheath requires continuous trophic support from the axon through [Neuregulin-1](/proteins/neuregulin-1) signaling, which binds to [ErbB2/ErbB3](/proteins/erbb2) receptors on Schwann cells. This bidirectional communication is essential for both Schwann cell survival and axonal integrity. [@ma2019]
Non-Myelinating Schwann Cells (Remak Cells)
Non-myelinating Schwann cells, also known as Remak cells, ensheath small-diameter unmyelinated axons. These cells provide metabolic support, maintain axonal homeostasis, and play important roles in nerve repair and regeneration following injury. [@jessen2015]
Support Functions
Schwann cells secrete various neurotrophic factors essential for neuronal survival and regeneration:
- [Nerve Growth Factor (NGF)nerve-growth-factor)
- [Brain-Derived Neurotrophic Factor (BDNF)brain-derived-neurotrophic-factor)
- [Glial Cell Line-Derived Neurotrophic Factor (GDNF)gdnf)
These cells also clear cellular debris after injury through phagocytosis and guide axonal regeneration by forming Bands of Büngner—pathways that direct regenerating axons to their targets. [@berger2018]
Blood-Nerve Barrier
Schwann cells contribute to the formation and maintenance of the blood-nerve barrier, which regulates the endoneurial microenvironment and protects peripheral nerves from harmful substances. This barrier function is critical for nerve health and is compromised in various neuropathies. [@stassart2013]
Development and Differentiation
Schwann cell development proceeds through distinct stages:
Mermaid diagram (expand to render)
[Neuregulin-1](/proteins/neuregulin-1) signaling through ErbB receptors is the primary molecular cue promoting Schwann cell differentiation toward the myelinating phenotype. Conversely, [Bone Morphogenetic Protein (BMP) signaling](/proteins/bmp-signaling) influences non-myelinating Schwann cell fate. [@saito2017]
Key transcription factors regulating Schwann cell development include:
- SOX10: Essential for neural crest specification and Schwann cell lineage commitment
- KROX20 (EGR2): Drives myelination program
- OCT2: Regulates myelin gene expression
Pathology in Peripheral Neuropathy
Charcot-Marie-Tooth Disease (CMT)
[Charcot-Marie-Tooth disease](/diseases/charcot-marie-tooth-disease) is the most common inherited peripheral neuropathy, affecting approximately 1 in 2,500 individuals. The disease encompasses a heterogeneous group of disorders classified as:
- CMT1 (Demyelinating): Caused by mutations in myelin genes including [PMP22](/genes/pmp22), [MPZ](/genes/mpz), and [GJB1](/genes/gjb1). These mutations impair myelin formation and maintenance, leading to reduced nerve conduction velocities.
- CMT2 (Axonal): Involves primary defects in axonal transport and mitochondrial function without primary demyelination.
- CMT4 (Autosomal Recessive): More severe forms with earlier onset.
The pathophysiology involves both primary Schwann cell dysfunction and secondary axonal loss. In CMT1, abnormal myelin protein expression leads to unstable myelin that degrades over time, resulting in secondary axonal degeneration. [@scherer2008]
Key genes implicated in CMT and their functions:
Diabetic Peripheral Neuropathy
[Diabetic peripheral neuropathy](/diseases/diabetic-neuropathy) affects over 50% of patients with diabetes and is a major cause of disability. Hyperglycemia damages Schwann cells through multiple mechanisms:
Metabolic Dysregulation: Glucose transporter dysfunction leads to impaired energy metabolism
Oxidative Stress: Mitochondrial dysfunction increases reactive oxygen species
Advanced Glycation End Products (AGEs): Accumulation damages cellular proteins and myelin
Polyol Pathway Activation: Sorbitol accumulation causes osmotic stressThese mechanisms impair Schwann cell function, reducing neurotrophic support and remyelination capacity. The resulting axonal degeneration leads to the characteristic sensory loss and neuropathic pain in diabetic neuropathy. [@feldman2017]
Guillain-Barré Syndrome
[Guillain-Barré syndrome](/diseases/guillain-barre-syndrome) and related autoimmune neuropathies (CIDP, MMN) involve immune-mediated attack on peripheral nerve components. Schwann cells are direct targets of autoantibodies and contribute to the inflammatory response by releasing cytokines and recruiting immune cells. [@martini2008]
Amyotrophic Lateral Sclerosis (ALS)
While primarily a [central nervous system disease](/diseases/amyotrophic-lateral-sclerosis), [ALS](/diseases/amyotrophic-lateral-sclerosis) also involves peripheral nervous system manifestations. Motor axon degeneration in the PNS occurs alongside central involvement, with impaired Schwann cell support potentially contributing to axonal disconnection.
Molecular Mechanisms of Schwann Cell Dysfunction
Myelin Dysfunction
In peripheral neuropathies, Schwann cells exhibit:
- Abnormal myelin protein expression and trafficking
- Impaired myelin maintenance and homeostasis
- Cycles of demyelination and remyelination
- Myelin outfoldings and tomacula formation
Schwann cells are highly metabolic and vulnerable to mitochondrial dysfunction:
- Glucose transporter (GLUT1) impairment
- Reduced ATP production
- Accumulation of oxidative stress
- Compromised calcium homeostasis
Inflammation
Schwann cells respond to nerve injury by:
- Releasing pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
- Recruiting macrophages to the site of injury
- Expressing MHC molecules that may trigger autoimmune responses
- Producing chemokines that guide immune cell infiltration
Epigenetic Regulation
Recent research demonstrates that epigenetic mechanisms, including DNA methylation and histone modifications, regulate Schwann cell function in neuropathy. Alterations in these mechanisms may contribute to disease progression and response to therapy. [@shan2021]
Schwann Cell Response to Injury
Following peripheral nerve injury, Schwann cells undergo dramatic changes:
Mermaid diagram (expand to render)
This regenerative capacity is a key feature of the peripheral nervous system and contrasts with the limited regeneration in the CNS. However, this capacity diminishes with age and in certain neuropathies. [@washbourne2015]
Therapeutic Implications
Neurotrophic Factor Delivery
Strategies to enhance Schwann cell survival and function through neurotrophic factors:
- [BDNF](/proteins/brain-derived-neurotrophic-factor) delivery promotes Schwann cell survival and axonal regeneration
- [GDNF](/proteins/gdnf) delivery supports motor neuron survival
- Gene therapy approaches for sustained factor expression
- Small molecule neurotrophic mimetics under development
Remyelination Strategies
Promoting remyelination in demyelinating neuropathies:
- Enhancing [cAMP signaling](/proteins/camp-signaling) to promote Schwann cell differentiation
- Blocking inhibitory molecules (Nogo, MAG) that prevent remyelination
- [BMP](/proteins/bmp-signaling) modulation to enhance myelination
- Pharmacological agents targeting myelin protein expression
Cell-Based Therapies
Schwann cell transplantation represents a promising approach:
- Autologous Schwann cell transplantation for nerve repair
- iPSC-derived Schwann cells as an unlimited cell source
- Combined Schwann cell and neural progenitor approaches
- Bioengineered tissue constructs for nerve guidance
Schwann cell transplantation has shown efficacy in models of peripheral nerve injury and is being explored for diabetic neuropathy. [@saporta2012]
Gene Therapy
Targeting disease-causing mutations in inherited neuropathies:
- Gene silencing using antisense oligonucleotides for [PMP22](/genes/pmp22) duplication
- CRISPR-based gene correction for specific mutations
- Gene replacement therapy for recessive mutations
- Delivery of protective genes (e.g., neurotrophic factors)
Exosome-Based Therapies
Schwann cells release extracellular vesicles (exosomes) that promote nerve regeneration:
- Exosome-mediated transfer of miRNAs and proteins
- Engineering exosomes for enhanced regenerative properties
- As cell-free alternatives to Schwann cell transplantation
These approaches show promise for treating peripheral neuropathies while avoiding issues associated with cell-based therapies. [@previdi2020]
Model Systems for Study
Animal Models
- Mouse models: Transgenic and knockout mice for CMT genes
- Zebrafish: Transparent embryos for live imaging of myelination
- Rat sciatic nerve injury models: Standard for regeneration studies
Cell Culture Models
- Primary Schwann cell cultures: From rodent and human peripheral nerves
- iPSC-derived Schwann cells: Patient-specific models for CMT and diabetic neuropathy
- Co-culture systems: Neuron-Schwann cell co-cultures for myelination studies
Organotypic Culture
- Explant cultures: Maintaining peripheral nerve segments in vitro
- 3D hydrogel systems: Engineered nerve tissues for study
Future Directions
Research directions with high potential include:
Single-cell RNA sequencing to characterize Schwann cell heterogeneity in different neuropathies
iPSC models from patients with specific mutations to test personalized therapies
Gene editing technologies for precise correction of disease-causing mutations
Biomarker development to identify patients likely to respond to specific therapies
Combination approaches targeting multiple pathways simultaneouslyClinical Features and Diagnosis
Clinical Presentation
Peripheral neuropathies involving Schwann cell dysfunction present with characteristic symptoms:
- Sensory symptoms: Numbness, tingling, burning pain, allodynia
- Motor symptoms: Weakness, muscle atrophy, foot drop
- Autonomic symptoms: Orthostatic hypotension, gastrointestinal dysfunction
In [Charcot-Marie-Tooth disease](/diseases/charcot-marie-tooth-disease), patients typically present in adolescence with distal muscle weakness, foot deformities (pes cavus, hammertoes), and diminished deep tendon reflexes. The disease progresses slowly but leads to significant disability over decades.
In [diabetic neuropathy](/diseases/diabetic-neuropathy), patients experience a symmetric, length-dependent pattern of neuropathy, starting in the feet and progressing proximally. Pain, often described as burning or stabbing, is a prominent feature in many patients.
Diagnostic Approaches
Clinical diagnosis involves:
Nerve conduction studies (NCS) and electromyography (EMG)
- Demyelinating CMT shows markedly slowed nerve conduction velocities (less than 38 m/s)
- Axonal CMT shows reduced compound muscle action potential amplitudes
- Diabetic neuropathy shows mixed demyelinating and axonal features
Nerve ultrasound and MRI
- Focal nerve enlargements in CMT1A (onion bulb formations)
- Nerve hypertrophy in chronic inflammatory neuropathies
Genetic testing
- Panel testing for CMT-associated genes
- PMP22 duplication analysis (CMT1A)
- Whole exome sequencing for atypical presentations
Skin biopsy
- Assessment of intraepidermal nerve fiber density
- Evaluation of sweat function for small fiber neuropathy
Biomarkers
Emerging biomarkers for Schwann cell-related neuropathies:
- Neurofilament light chain (NfL): Blood marker for axonal degeneration
- Toward-specific biomarkers: Antibodies against P0, PMP22, neurofascin
- Schwann cell-derived exosomal miRNAs: Potential diagnostic markers
- Proteomic signatures: Identification of disease-specific protein patterns
Animal Models of Schwann Cell Pathology
Spontaneous Mutant Models
- C3H/HeJ mice: Spontaneous demyelination phenotype
- Trembler (Tr) mice: PMP22 point mutation causing demyelination
- Wistar diabetic rats: Spontaneous diabetic neuropathy
Transgenic Models
- PMP22 transgenic mice: Overexpression models for CMT1A
- MPZ knockout mice: For CMT1B studies
- GJB1 knockout mice: For CMT1X studies
- Mitochondria-specific mutants: For axonal CMT models
Induced Models
- Streptozotocin-induced diabetes: For diabetic neuropathy
- CRISPR-edited models: Patient-specific mutations introduced
- Humanized mouse models: Expressing human disease genes
Comparative Biology
Key insights from animal models:
Schwann Cell Interactions with Other Cell Types
Neuron-Schwann Cell Interactions
The relationship between neurons and Schwann cells is mutually dependent:
- Axonal signals: [Neuregulin-1](/proteins/neuregulin-1) type III is critical for Schwann cell survival and myelination
- Schwann cell signals: Neurotrophins (NGF, BDNF) support neuronal health
- Electrical activity: Action potentials promote Schwann cell proliferation and myelination
- Synaptic-like contacts: Neurons form direct communication with Schwann cells
Schwann Cell-Macrophage Interactions
Following nerve injury, Schwann cells and macrophages coordinate cleanup and regeneration:
- Dual roles: Schwann cells both recruit and later suppress macrophages
- Phagocytosis: Macrophages clear myelin debris that Schwann cells cannot fully digest
- Repair phenotype: M2 macrophages promote regeneration through anti-inflammatory signals
- Cross-talk: cytokines including IL-10 and TGF-β regulate the repair response
Schwann Cell-Endothelial Interactions
The blood-nerve barrier involves coordinated signaling:
- VEGF signaling: Schwann cells produce VEGF affecting endothelial cells
- Tight junction maintenance: Endothelial-Schwann cell crosstalk maintains barrier integrity
- Inflammatory responses: Barrier breakdown in inflammatory neuropathies
- Angiogenesis: New vessel formation in nerve regeneration
Immunological Aspects
Autoimmune Neuropathies
Schwann cells are targets in several autoimmune peripheral neuropathies:
- Guillain-Barré syndrome: Anti-ganglioside antibodies cross-react with Schwann cell antigens
- Chronic inflammatory demyelinating polyneuropathy (CIDP): T-cell mediated attack on myelin
- Multifocal motor neuropathy (MMN): Anti-GM1 antibodies affecting nodes of Ranvier
- Paraneoplastic neuropathies: Remote effects of cancer on peripheral nerve
Schwann Cell Antigen Presentation
Schwann cells can present antigens through MHC class I and II:
- MHC class I: Enables cytotoxic T-cell recognition
- MHC class II: Allows interaction with CD4+ T-helper cells
- Costimulatory molecules: Expressing CD80/CD86 for full activation
- Implications for autoimmunity: Potential trigger for autoimmune responses
Regeneration Biology
Extrinsic Factors Affecting Regeneration
Age: Schwann cell reactivity declines with age
Distance: Longer gaps correlate with poorer outcomes
Inflammation: Chronic inflammation impairs regeneration
Systemic diseases: Diabetes, vascular disease impair regenerationIntrinsic Schwann Cell Factors
- cAMP levels: Higher cAMP enhances Schwann cell plasticity
- JNK signaling: Required for dedifferentiation
- SOX2 expression: Promotes proliferation and dedifferentiation
- Notch signaling: Maintains dedifferentiated state
- Laminin: Essential for Schwann cell migration and myelination
- Integrins: Cell surface receptors for ECM proteins
- Matrix metalloproteinases: Remodel ECM during regeneration
- Hyaluronic acid: Forms channels for regenerating axons
Pharmacological Interventions
Currently Available Treatments
Disease-specific therapies
- Ascorbic acid (high-dose): May benefit some CMT1A patients
- Vitamin B complex: For nutritional neuropathies
- Immunomodulation: IVIG, steroids for inflammatory neuropathies
Symptomatic treatments
- Neuropathic pain agents: Gabapentin, pregabalin, duloxetine
- Orthopedic interventions: Ankle-foot orthoses, surgical correction
- Physical therapy: Maintain mobility and prevent contractures
Emerging Pharmacological Approaches
Combination Strategies
Rational combinations under investigation:
- Gene therapy + neurotrophic factors: Synergistic effects
- Immunomodulation + regeneration promoters: For inflammatory neuropathies
- Small molecule + cell therapy: Enhanced nerve repair
- Physical therapy + pharmacological enhancement: Maximizing functional recovery
Socioeconomic Impact
Disease Burden
Peripheral neuropathies represent a significant healthcare burden:
- Prevalence: Over 20 million people in the United States alone affected
- Economic cost: Estimated $10-15 billion annually in direct and indirect costs
- Quality of life: Significant impact on daily activities, employment
- Caregiver burden: Substantial impact on family members
Healthcare Utilization
- Diagnostic workup: Often requires multiple specialists
- Treatment visits: Regular neurologist, physical therapy, orthopedic care
- Assistive devices: Wheelchairs, orthotics, home modifications
- Lost productivity: Early retirement, reduced work capacity
Research Methods and Techniques
Histopathology
Classical approaches to studying Schwann cell pathology:
- Teased fiber preparations: Visualization of myelin internodes
- Electron microscopy: Ultrastructural analysis of myelin and axons
- Immunohistochemistry: Detection of specific Schwann cell markers
- S100 protein: General Schwann cell marker
- P0 (MPZ): Myelinating Schwann cell specific
- c-Jun: Dedifferentiated Schwann cell marker
- p75NTR: Immature Schwann cell marker
Molecular Techniques
Modern approaches to understanding Schwann cell biology:
- Single-cell RNA sequencing: Profiling Schwann cell populations
- ATAC-seq: Chromatin accessibility mapping
- Proteomics: Identification of disease-associated protein changes
- Metabolomics: Metabolic state characterization
Functional Assays
- Myelination in vitro: Co-culture with neurons
- Migration assays: Wound healing and chemotaxis
- Phagocytosis assays: Myelin clearance capacity
- Electrophysiology: Node of Ranvier analysis
Notable Research Milestones
Ethical Considerations in Research
Animal Use
- 3Rs principles in peripheral nerve research
- Development of alternative in vitro models
- Translating findings from rodents to humans
Genetic Testing
- Informed consent for genetic testing
- Counseling for patients and families
- Implications for family members
- Privacy and discrimination concerns
Clinical Trial Design
- Patient recruitment challenges
- Outcome measure standardization
- Long-term follow-up requirements
- Equitable access to experimental treatments
Global Research Initiatives
Large-Scale Studies
- Inherited Neuropathy Consortium (INC): Multi-center CMT registry
- Diabetic Neuropathy Consortium: Biomarker discovery
- European CMT Registry: Natural history studies
Research Networks
- NCATS Rare Diseases Research: NIH-supported networks
- CMT Research Foundation: Patient-driven research funding
- Peripheral Nerve Society: Professional organization
Collaborative Projects
- Gene therapy consortia: Sharing viral vectors and protocols
- Biobank initiatives: Tissue and DNA banking
- Data sharing platforms: Clinical and genetic databases
Convergence with CNS Research
Oligodendrocyte Comparisons
While [Schwann cells](/cell-types/schwann-cells-peripheral-neuropathy) myelinate the [PNS](/brain-regions/peripheral-nervous-system) and [oligodendrocytes](/cell-types/oligodendrocytes) myelinate the [central nervous system](/brain-regions/central-nervous-system), they share many molecular mechanisms:
- Similar myelin protein expression patterns
- Analogous signaling pathways for myelination
- Parallel demyelination-remyelination processes
- Shared therapeutic target pathways
Cross-Disease Insights
Research on peripheral neuropathies informs understanding of:
- [Multiple sclerosis](/diseases/multiple-sclerosis): Demyelination mechanisms
- [ALS](/diseases/amyotrophic-lateral-sclerosis): Neuroimmune interactions
- [Alzheimer's disease](/diseases/alzheimers-disease): Neuron-glia relationships
Conclusion
Schwann cells are essential for peripheral nerve function and their dysfunction underlies many peripheral neuropathies. Understanding the molecular mechanisms of Schwann cell pathology provides opportunities for developing disease-modifying therapies. From gene therapy for inherited neuropathies to cell-based approaches for diabetic neuropathy, targeting Schwann cells offers promise for treating conditions that affect millions worldwide.
References
[Scherer & Wrabetz, Molecular mechanisms of Charcot-Marie-Tooth disease (2008)](https://pubmed.ncbi.nlm.nih.gov/18543321/)
[Feldman et al., Diabetic neuropathy: ADA position statement (2017)](https://pubmed.ncbi.nlm.nih.gov/28209815/)
[Niemann et al., Animal models of inherited neuropathies (2006)](https://pubmed.ncbi.nlm.nih.gov/16583170/)
[Saporta et al., Schwann cell transplantation in models of peripheral neuropathy (2012)](https://pubmed.ncbi.nlm.nih.gov/22410376/)
[Berger et al., Glia-neuron interactions in peripheral nerve repair (2018)](https://pubmed.ncbi.nlm.nih.gov/29755329/)
[Faroni et al., Schwann cell differentiation and nerve regeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/26238160/)
[Nave, Myelination and trophic support of long axons (2010)](https://pubmed.ncbi.nlm.nih.gov/20308745/)
[Stassart et al., Schwann cells in blood-nerve barrier formation (2013)](https://pubmed.ncbi.nlm.nih.gov/23361857/)
[Ma et al., Neuregulin-1 signaling in Schwann cell development (2019)](https://pubmed.ncbi.nlm.nih.gov/30639289/)
[Shan et al., Epigenetic regulation in Schwann cell function (2021)](https://pubmed.ncbi.nlm.nih.gov/33306098/)
[Jessen & Mirsky, Schwann cell development (2015)](https://pubmed.ncbi.nlm.nih.gov/25726178/)
[Martini et al., Schwann cell-immune system interactions (2008)](https://pubmed.ncbi.nlm.nih.gov/18615560/)
[Washbourne, Glia-neuron interactions in nervous system development (2015)](https://pubmed.ncbi.nlm.nih.gov/25808226/)
[Previdi et al., Schwann cell-derived exosomes in nerve regeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/31929115/)
[Saito et al., BMP signaling in Schwann cell development (2017)](https://pubmed.ncbi.nlm.nih.gov/28483710/)
[Shamorsky et al., Exosome-based therapeutics for nerve regeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35078056/)
[Shen et al., Schwann cell extracellular vesicles in nerve repair (2020)](https://pubmed.ncbi.nlm.nih.gov/32116569/)
[Povel et al., Genes for hereditary neuropathy (2019)](https://pubmed.ncbi.nlm.nih.gov/30745434/)
[Hu et al., Schwann cell proliferation and migration (2003)](https://pubmed.ncbi.nlm.nih.gov/14514020/)
[Combes et al., Schwann cells in peripheral nerve repair (2014)](https://pubmed.ncbi.nlm.nih.gov/25474741/)See Also
- [Charcot-Marie-Tooth Disease](/diseases/charcot-marie-tooth-disease)
- [Diabetic Neuropathy](/diseases/diabetic-neuropathy)
- [Guillain-Barré Syndrome](/diseases/guillain-barre-syndrome)
- [PMP22 Gene](/genes/pmp22)
- [MPZ Gene](/genes/mpz)
- [Myelin Basic Protein](/proteins/myelin-basic-protein)
- [Neuregulin-1 Signaling](/proteins/neuregulin-1)
- [Peripheral Nervous System](/brain-regions/peripheral-nervous-system)
- [Nerve Regeneration](/mechanisms/nerve-regeneration)